Real‐World Outcomes of Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma: Analyzing Patient‐Specific Factors Influencing Survival and Response Rate

ABSTRACT Background Head and neck squamous cell carcinoma (HNSCC) is a globally significant disease with poor survival outcomes. Immune checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab have improved treatment paradigms, yet their real‐world efficacy and the factors influencing treatm...

Descripció completa

Dades bibliogràfiques

Autors principals:	Lena Huber, Constanze Kohler, Anne Lammert, Claudia Scherl, Sonja Ludwig, Annette Affolter, Nicole Rotter, Frederic Jungbauer
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2025-11-01
Col·lecció:	Cancer Reports
Matèries:	head and neck squamous cell carcinoma immune checkpoint inhibitors immunotherapy response nivolumab pembrolizumab predictive biomarkers
Accés en línia:	https://doi.org/10.1002/cnr2.70369
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!